Spravato is emerging as a transformative way to relieve symptoms of depression for those who have not had success with conventional treatments. Clinical advances have made it possible to harness the profound healing power of ketamine through controlled administration. This advanced treatment is highly effective in treating depression and suicidal ideation, offering rapid and long-lasting symptom relief.
Individuals interested in improving their mental health may have questions about how Spravato works and whether it is right for them. Our dedicated team at NeuroPsych Wellness Center is here to help you understand what to expect from your Spravato treatments so you can make an informed decision for your care. Take a look at these Spravato FAQs and then reach out to our team for personalized guidance on how this treatment can benefit you.
A common question people have is whether Spravato is safe and approved by the FDA. Spravato is fully cleared by the Food and Drug Administration (FDA) to treat treatment-resistant depression (TRD) and suicidal ideation (SI) in adults. It was first cleared in 2019 as an adjunct therapy to traditional antidepressants, though in 2025 the FDA granted clearance for Spravato as a monotherapy. This vastly expands the healing potential of Spravato to reach a wider pool of candidates.
Spravato is clinically proven to quickly and effectively treat symptoms of depression, especially in patients who have not had success with traditional methods. Research shows that 88% of patients experienced a significant reduction in symptoms of depression after three months of Spravato use, some of whom felt a complete resolution of symptoms. This esketamine-based nasal spray is most effective when administered on a phase-based dosing schedule, typically beginning with 8 weeks of treatment that decreases in consistency over time.
One of the biggest benefits of Spravato is its ability to offer fast-acting relief for those experiencing depressive or suicidal thoughts. Most patients report a reduction in symptoms just 24 hours after their first Spravato dose, and these effects continue to improve over time. The quick results of this esketamine-based nasal spray are one of the key factors that set this depression treatment apart from others, making it a good choice for those experiencing acute emotional crisis. If you are having a mental health emergency, however, please seek immediate mental health attention.
The main compound in Spravato is esketamine, which has sedative effects. As a result, some patients may experience short-term drowsiness, dizziness, or a sense of dissociation during or after treatment. Because of these potential side effects, patients are required to arrange reliable transportation home following each session. Our top priority is your safety.
If you are an adult in good physical health with treatment-resistant depression or suicidal ideation, you may be a candidate for Spravato. Patients with certain uncontrolled medication conditions, such as hypertension or a history of brain bleeds or substance abuse, may not be eligible for Spravato. If you are pregnant or nursing, you should not take Spravato.
The best way to know if you are a candidate for Spravato is by scheduling an initial evaluation at our office. Here, one of our board-certified providers will ask you questions about your medical and psychiatric history and perform an initial mental health evaluation. Once we get a sense of your needs and goals, we can determine your eligibility for treatments and begin scheduling you for your initial Spravato sessions.
For patients with treatment-resistant depression, Spravato can be a lifesaving medication. If you have more questions after reading these Spravato FAQs, contact our dedicated team to discuss any questions or concerns you may have about this innovative treatment.